Piascik M T, Smith M S, Soltis E E, Perez D M
Department of Pharmacology, College of Medicine, University of Kentucky, Lexington 40536.
Mol Pharmacol. 1994 Jul;46(1):30-40.
In situ hybridization histochemistry, radioligand binding, and in vitro contractile studies were used to characterize the vascular distribution of the recently discovered alpha 1D-adrenoceptor. In situ hybridization with an antisense probe localized the mRNA for the alpha 1D-adrenoceptor to the medial layer of the rat aorta renal and mesenteric resistance arteries. If the tissues were first treated with RNase or a sense probe was used, no specific hybridization signal was detected. The extent to which this receptor was expressed as protein was assessed with radioligand binding studies. A series of ligands used to characterize alpha 1-adrenoceptors interacted with two sites labeled by [3H]prazosin in homogenates from the aorta and mesenteric vascular bed. The high affinity site had the characteristics of an alpha 1A-adrenoceptor. However, the low affinity site had ligand binding characteristics distinct from those of the alpha 1D-adrenoceptor or any other known alpha 1-adrenoceptor subtype. mRNA for the alpha 1B- and alpha 1C-adrenoceptors was also detected in the aorta, renal arteries, and mesenteric resistance arteries. Chloroethylclonidine (CEC) (1 and 10 microM) had differential effects on phenylephrine-induced contractions of vascular smooth muscle. CEC completely inhibited the response in the aorta and caused a partial inhibition in the mesenteric resistance artery. The same concentrations of CEC had little effect on phenylephrine responses in the renal artery. The data suggest the following. 1) mRNA for the novel alpha 1D-adrenoceptor is localized in vascular smooth muscle. 2) Definitive identification of expression of this receptor was not possible; this may be related to coexpression of other subtypes of alpha 1-adrenoceptors. 3) mRNA for the alpha 1C-adrenoceptor was detected in rat peripheral vasculature. 4) The alpha 1A-adrenoceptor is also localized in the vasculature. 5) Three and possibly four alpha 1-adrenoceptors participate in vascular smooth muscle regulation.
采用原位杂交组织化学、放射性配体结合及体外收缩研究来表征最近发现的α1D -肾上腺素能受体的血管分布。用反义探针进行原位杂交将α1D -肾上腺素能受体的mRNA定位于大鼠主动脉、肾动脉和肠系膜阻力动脉的中层。如果组织先用核糖核酸酶处理或使用正义探针,则未检测到特异性杂交信号。通过放射性配体结合研究评估该受体表达为蛋白质的程度。一系列用于表征α1 -肾上腺素能受体的配体与主动脉和肠系膜血管床匀浆中由[3H]哌唑嗪标记的两个位点相互作用。高亲和力位点具有α1A -肾上腺素能受体的特征。然而,低亲和力位点的配体结合特征与α1D -肾上腺素能受体或任何其他已知的α1 -肾上腺素能受体亚型不同。在主动脉、肾动脉和肠系膜阻力动脉中也检测到了α1B -和α1C -肾上腺素能受体的mRNA。氯乙可乐定(CEC)(1和10微摩尔)对去氧肾上腺素诱导的血管平滑肌收缩有不同影响。CEC完全抑制主动脉中的反应,并在肠系膜阻力动脉中引起部分抑制。相同浓度的CEC对肾动脉中去氧肾上腺素的反应几乎没有影响。数据表明如下:1)新型α1D -肾上腺素能受体的mRNA定位于血管平滑肌中。2)无法明确鉴定该受体的表达;这可能与α1 -肾上腺素能受体其他亚型的共表达有关。3)在大鼠外周血管中检测到了α1C -肾上腺素能受体的mRNA。4)α1A -肾上腺素能受体也定位于血管系统中。5)三种可能还有四种α1 -肾上腺素能受体参与血管平滑肌调节。